Alexander Brun, MD
Gastroenterology · Brooklyn, NYNPI 1164735072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,875 of the $54,706 with a category attached, or 71.1%. AbbVie accounts for 79.5% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $20,518 and has fallen 95.5% since, to $925 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 890 payments — averaging $61.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$43K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
- Vivus LLC$801
- Gilead$757
- Ironwood Pharmaceuticals, Inc$535
- Takeda Pharmaceuticals U.S.A., Inc.$502
- plus $5K from 30 others
Across 42 payments — averaging $10,720 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$179K
- AbbVie$122K
- AstraZeneca$101K
- Sanofi$20K
- Genentech, Inc.$15K
- Swing Therapeutics, Inc.$14K
What the payments were for
- Consulting fees$210%
- Speaking & faculty fees$38,87571%
- Food & beverage$15,76529%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 218 | $43,487 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 283 | $3,597 |
| Vivus LLC | 50 | $801 |
| Gilead | 38 | $757 |
| Ironwood Pharmaceuticals, Inc | 26 | $535 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $502 |
| Ardelyx, Inc. | 17 | $495 |
| QOL Medical, LLC | 19 | $484 |
| Madrigal Pharmaceuticals | 9 | $445 |
| Bristol Myers Squibb | 26 | $401 |
| Nestle Healthcare Nutrition Inc. | 25 | $375 |
| Johnson & Johnson | 19 | $341 |
| Redhill Biopharma Inc. | 17 | $281 |
| Aimmune Therapeutics, Inc. | 9 | $226 |
| Ferring Pharmaceuticals Inc. | 10 | $218 |
| Intra-sana Laboratories | 15 | $206 |
| Pfizer | 11 | $194 |
| Phathom Pharmaceuticals, Inc. | 12 | $183 |
| Merck | 10 | $180 |
| Intercept Pharmaceuticals, Inc. | 9 | $175 |
| Shionogi Inc | 7 | $134 |
| Braintree Laboratories, Inc. | 6 | $110 |
| AstraZeneca | 1 | $101 |
| Concordia Pharmaceuticals Inc. | 5 | $83 |
| Regeneron Healthcare Solutions, Inc. | 4 | $81 |
| Romark Laboratories, LC | 3 | $61 |
| Sanofi | 3 | $53 |
| Shield Therapeutics Inc | 2 | $47 |
| Evoke Pharma, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Amgen | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| Capsovision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,706 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 164 | $452,855 |
| LinzessLinaclotide | 289 | $218,358 |
| CreonLipase/Protease/Amylase | 88 | $218,314 |
| Dexlansoprazole DrDexlansoprazole | 192 | $48,365 |
| TrulancePlecanatide | 20 | $21,551 |
| DexilantDexlansoprazole | 67 | $20,627 |
| CanasaMesalamine | 18 | $19,651 |
| Mesalamine | 26 | $11,987 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 51 | $8,088 |
| Pantoprazole Sodium | 499 | $4,158 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 67 | $3,914 |
| Ursodiol | 37 | $3,472 |
| Sucralfate | 40 | $3,379 |
| Famotidine | 210 | $2,073 |
| Esomeprazole Magnesium | 21 | $681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $226 | $452,855164 claims |
| AbbVieLinzess, Creon | $43,487 | $436,672377 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $3,597 | $21,55120 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $502 | $20,62767 claims |
| Ironwood Pharmaceuticals, IncCanasa | $535 | $19,65118 claims |
| Braintree Laboratories, Inc.Sutab | $110 | $8,08851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Brooklyn
- Sam MoskowitzBrooklyn$332K
- Jianjun LiBrooklyn$211K
- Nison BadalovBrooklyn$200K
- Kevin TinBrooklyn$168K
- Jonathan ErberBrooklyn$164K
- Rabin RahmaniBrooklyn$155K
- Kayane Hanna-HindyBrooklyn$151K
- Kadirawelpillai IswaraBrooklyn$148K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.